Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
1.098
-0.042 (-3.69%)
At close: Apr 1, 2025, 4:00 PM
1.101
+0.003 (0.26%)
Pre-market: Apr 2, 2025, 4:08 AM EDT

Virax Biolabs Group Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Virax Biolabs Group stock has a target of 3.00, which predicts an increase of 173.25% from the current stock price of 1.10.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $3.00 $3.00 $3.00 $3.00
Change +173.25% +173.25% +173.25% +173.25%

Analyst Ratings

According to 1 stock analyst, the rating for Virax Biolabs Group is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Mar '25
Strong Buy 1
Buy 0
Hold 0
Sell 0
Strong Sell 0
Total 1

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$3
Strong Buy Initiates $3 +173.25% Mar 31, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
8.24M
from 156.42K
Increased by 5,169.18%
Revenue Next Year
13.76M
from 8.24M
Increased by 66.97%
EPS This Year
-0.06
from -3.36
EPS Next Year
0.04
from -0.06
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Mar 31, 2020 Mar 31, 2021 Mar 31, 2022 Mar 31, 2023 Mar 31, 2024 Mar 31, 2025 Mar 31, 2026
Revenue
99.88K123.82K-8.56K156.42K8.24M13.76M
Revenue Growth
-23.97%--1,727.11%5,169.18%66.97%
EPS
-6.81-2.71-1.79-5.13-3.36-0.060.04
EPS Growth
-------
Forward PE
------26.91
No. Analysts -----33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026
High 8.5M 14.2M
Avg 8.2M 13.8M
Low 7.9M 13.2M

Revenue Growth

Revenue Growth 20252026
High
5,323.9%
71.9%
Avg
5,169.2%
67.0%
Low
4,962.0%
60.4%

EPS Forecast

EPS 20252026
High -0.06 0.04
Avg -0.06 0.04
Low -0.06 0.04

EPS Growth

EPS Growth 20252026
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.